10.3390/nu8010053 [DOI] [PMC free article] [PubMed] [Google Scholar] 69.Liu J, Sun Y, Zhang H, Ji D, Wu F, Tian H, et al
Here is a quick snapshot of where each medication stands: Tirzepatide (brand names: Mounjaro for diabetes, Zepbound for weight loss): Greater average weight loss in trials, dual receptor mechanism, no FDA-approved cardiovascular outcomes indication as of 2026 Semaglutide (brand names: Ozempic for diabetes, Wegovy for weight loss): Slightly lower average weight loss, single receptor mechanism, FDA-approved for reducing major cardiovascular events in patients with established heart disease Administration: Both are once-weekly injections
If you are researching these options, the single most valuable next step is a clinical consultation not more forum posts
This section explores both the side effects on cardiovascular health and the specific heart rate changes observed in users
Theyre part of the metabolic equation
Get the blood test done early
